K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer

被引:136
作者
Fukuyama, Y
Mitsudomi, T
Sugio, K
Ishida, T
Akazawa, K
Sugimachi, K
机构
[1] AICHI CANC CTR HOSP,DEPT THORAC SURG,AICHI,JAPAN
[2] KYUSHU UNIV,FAC MED,DEPT MED INFORMAT,FUKUOKA 812,JAPAN
关键词
K-ras; p53; mutation; lung cancer;
D O I
10.1038/bjc.1997.194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras(+)) and 57 (35.8%) had mutations of the p53 (p53(+)). There were 95 cases (59.7%) with ras (-)p53(-), seven cases (4.4%) with ras+/p53(-), 53 cases (33.3%) with ras (-)/p53(+) and four cases (2.5%) with ras(+)/p53(+). The ras(+) group had a worse prognosis than the ras(-) group in all cases and in 107 early-stage cases (stage I-II, P<0.05). The p53(+) group had a worse prognosis in 107 early-stage cases (P<0.01), but there was no statistically significant difference when 52 advanced-stage cases (stage III-IV) or all patients were considered. Both ras and p53 mutations were unfavourable prognostic factors in 94 cases with adenocarcinoma, but there was no statistical significance in 57 cases with squamous cell carcinoma. According to Cox's model, the pathological stage, ms mutation and p53 mutation were found to be independent prognostic factors. Our results suggest that ras and p53 mutations were independent unfavourable prognostic markers especially in the early stage of NSCLC or in adenocarcinoma.
引用
收藏
页码:1125 / 1130
页数:6
相关论文
共 40 条
[1]   TP53 MUTATIONS AND BREAST-CANCER PROGNOSIS - PARTICULARLY POOR SURVIVAL RATES FOR CASES WITH MUTATIONS IN THE ZINC-BINDING DOMAINS [J].
BORRESEN, AL ;
ANDERSEN, TI ;
EYFJORD, JE ;
CORNELIS, RS ;
THORLACIUS, S ;
BORG, A ;
JOHANSSON, U ;
THEILLET, C ;
SCHERNECK, S ;
HARTMAN, S ;
CORNELISSE, CJ ;
HOVIG, E ;
DEVILEE, P .
GENES CHROMOSOMES & CANCER, 1995, 14 (01) :71-75
[2]  
BOS JL, 1989, CANCER RES, V49, P4682
[3]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[4]   PARTICIPATION OF P53 CELLULAR TUMOR-ANTIGEN IN TRANSFORMATION OF NORMAL EMBRYONIC-CELLS [J].
ELIYAHU, D ;
RAZ, A ;
GRUSS, P ;
GIVOL, D ;
OREN, M .
NATURE, 1984, 312 (5995) :646-649
[5]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[6]  
HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571
[7]  
HOPKINS A, 1990, BMDP STATISTICAL SOF, V2, P769
[8]  
HORIO Y, 1993, CANCER RES, V53, P1
[9]   COOPERATION BETWEEN ONCOGENES [J].
HUNTER, T .
CELL, 1991, 64 (02) :249-270
[10]   INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER [J].
IGGO, R ;
GATTER, K ;
BARTEK, J ;
LANE, D ;
HARRIS, AL .
LANCET, 1990, 335 (8691) :675-679